---
title: Treatment of Relapsed/Refractory MCL
date: '2024-07-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39059015/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240727183028&v=2.18.0.post9+e462414
source: Blood
description: Mantle cell lymphoma is a rare subtype of B-cell Non-Hodgkin-lymphoma
  which is clinically characterized by its heterogeneous behaviour with courses ranging
  from indolent to highly aggressive cases with limited prognosis. Targeted treatment
  alternatives in first-line and relapse settings are more and more shaping the therapeutic
  landscape of MCL. The development and implementation of new targeted and immunotherapeutic
  approaches have already improved outcomes for MCL patients with refractory ...
disable_comments: true
---
Mantle cell lymphoma is a rare subtype of B-cell Non-Hodgkin-lymphoma which is clinically characterized by its heterogeneous behaviour with courses ranging from indolent to highly aggressive cases with limited prognosis. Targeted treatment alternatives in first-line and relapse settings are more and more shaping the therapeutic landscape of MCL. The development and implementation of new targeted and immunotherapeutic approaches have already improved outcomes for MCL patients with refractory ...